Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Asset Writedowns and Impairment (2023 - 2025)

Autolus Therapeutics posted quarterly Asset Writedowns and Impairment of -$7.2 million for Q4 2025, down 1646.38% year-on-year from $467544.5 in Q4 2024, and down 1646.38% on a QoQ basis from -$414000.0 in Q4 2024.

Autolus Therapeutics (AUTL) has 3 years of Asset Writedowns and Impairment data on file, last reported at -$7.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 1646.38% year-over-year to -$7.2 million; the trailing twelve-month figure through Dec 2025 stood at -$7.6 million (changed N/A YoY), and the FY2025 full-year result was $349000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 stood at -$7.2 million, down from -$414000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $414000.0 in Q2 2024 and bottomed at -$7.2 million in Q4 2025.
  • The 3-year median for Asset Writedowns and Impairment is -$16000.0 (2023), against an average of -$1.7 million.
  • Peak annual rise in Asset Writedowns and Impairment reached 1646.38% in 2025, while the deepest fall reached 1646.38% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $382000.0 in 2023, then slumped by 208.38% to -$414000.0 in 2024, then sank by 1646.38% to -$7.2 million in 2025.
  • The last three Asset Writedowns and Impairment figures came in at -$7.2 million (Q4 2025), -$414000.0 (Q4 2024), and $414000.0 (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Autolus Therapeutics - - -1.04 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -7.23 Mn
Dec 31, 2025 -7.23 Mn
Dec 31, 2024 -414,000.00
Dec 31, 2024 -414,000.00
Jun 30, 2024 414,000.00
Jun 30, 2024 414,000.00
Sep 30, 2023 382,000.00
Sep 30, 2023 382,000.00